In my opinion, this whole process has been about being a poster child for a new regulatory program while buying time for Flaskworks, optimizing the quality life years from survivors for reimbursement purposes, planning for Real World Evidence and Data to be developed through IFRs for use in an expanded label for all solid tumor cancers and generally getting the regulatory house in order to do all of this and make a huge step forward in the way future trials will be conducted. Investors are being asked to be patient throughout this whole process while not being given anything but hints about the transformation going on in which every step seemingly requires a “bigger boat” for NWBO; ). Best wishes.
Market Data 
Markets 
AI
